These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 9547132)

  • 41. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
    Tollefson GD; Birkett M; Koran L; Genduso L
    J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
    Foa EB; Simpson HB; Rosenfield D; Liebowitz MR; Cahill SP; Huppert JD; Bender J; McLean CP; Maher MJ; Campeas R; Hahn CG; Imms P; Pinto A; Powers MB; Rodriguez CI; Van Meter PE; Vermes D; Williams MT
    J Clin Psychiatry; 2015 Apr; 76(4):440-6. PubMed ID: 25375780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK; Kozak MJ; Liebowitz M; White KL
    Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.
    Hoehn-Saric R; Ninan P; Black DW; Stahl S; Greist JH; Lydiard B; McElroy S; Zajecka J; Chapman D; Clary C; Harrison W
    Arch Gen Psychiatry; 2000 Jan; 57(1):76-82. PubMed ID: 10632236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder.
    Koran LM; Hackett E; Rubin A; Wolkow R; Robinson D
    Am J Psychiatry; 2002 Jan; 159(1):88-95. PubMed ID: 11772695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Panic attacks precipitated by sertraline.
    Zinner SH
    Am J Psychiatry; 1994 Jan; 151(1):147-8. PubMed ID: 8267115
    [No Abstract]   [Full Text] [Related]  

  • 50. Obsessive-compulsive disorder: a new perspective in diagnosis and treatment.
    Lydiard RB
    Int Clin Psychopharmacol; 1994 Jun; 9 Suppl 3():33-7. PubMed ID: 7963449
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder.
    Crockett BA; Churchill E; Davidson JR
    Ann Clin Psychiatry; 2004; 16(3):127-32. PubMed ID: 15517844
    [TBL] [Abstract][Full Text] [Related]  

  • 52. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Afshar H; Roohafza H; Mohammad-Beigi H; Haghighi M; Jahangard L; Shokouh P; Sadeghi M; Hafezian H
    J Clin Psychopharmacol; 2012 Dec; 32(6):797-803. PubMed ID: 23131885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
    Riddle MA; Reeve EA; Yaryura-Tobias JA; Yang HM; Claghorn JL; Gaffney G; Greist JH; Holland D; McConville BJ; Pigott T; Walkup JT
    J Am Acad Child Adolesc Psychiatry; 2001 Feb; 40(2):222-9. PubMed ID: 11211371
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
    BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study.
    Van Ameringen MA; Lane RM; Walker JR; Bowen RC; Chokka PR; Goldner EM; Johnston DG; Lavallee YJ; Nandy S; Pecknold JC; Hadrava V; Swinson RP
    Am J Psychiatry; 2001 Feb; 158(2):275-81. PubMed ID: 11156811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.
    Rutrick D; Stein DJ; Subramanian G; Smith B; Fava M; Hasler G; Cha JH; Gasparini F; Donchev T; Ocwieja M; Johns D; Gomez-Mancilla B
    Adv Ther; 2017 Feb; 34(2):524-541. PubMed ID: 28044255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
    Rosenbaum JF; Fava M; Hoog SL; Ascroft RC; Krebs WB
    Biol Psychiatry; 1998 Jul; 44(2):77-87. PubMed ID: 9646889
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Aboujaoude E; Barry JJ; Gamel N
    J Clin Psychopharmacol; 2009 Feb; 29(1):51-5. PubMed ID: 19142108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.